WHNP Boards Exam Prep Document | 2026/2027 Edition |
150 Verified Questions - 150 Questions with Answers
WHNP Boards 2026-150 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for candidates aspiring to pass
the Women's Health Nurse Practitioner (WHNP) board certification. It contains 150 verified questions
and answers that reflect the current scope and standards of practice, ensuring a thorough review of
essential clinical and theoretical knowledge. Each question is accompanied by expert solutions and
rationales, designed to reinforce learning and test-taking strategies. This resource is an indispensable
tool for achieving a high score on the WHNP boards in the 2026-2027 academic year.
Key Features:
Comprehensive review of primary care in women's health across the lifespan
In-depth coverage of reproductive health and contraception management
Detailed questions on prenatal, intrapartum, and postpartum care
Focus on gynecological disorders and common infections
Menopause and perimenopause management strategies
Breast health assessment and disease management
Sexually transmitted infections (STIs) screening and treatment
Infertility evaluation and basic management
Adolescent gynecology and pediatric gynecological concerns
Health promotion, screening, and disease prevention guidelines
Pharmacology relevant to women's health practice
Evidence-based practice and research utilization
Ethical and legal issues in women's health
Cultural competence and patient-centered care
Interprofessional collaboration and referral pathways
Patient education and counseling techniques
Quality improvement and safety in clinical practice
Professional role and leadership in advanced practice nursing
Updates for 2026:
- Updated to align with the latest NCC WHNP exam blueprint and competencies
- Incorporates 2026 clinical practice guidelines from ACOG, USPSTF, and CDC
- Includes new questions on telehealth and digital health in women's health
- Reflects current evidence on LGBTQ+ health considerations and inclusive care
- Enhanced rationales with recent research findings and expert consensus
Abstract:
This exam preparation document is a scholarly compilation of 150 board-style questions and answers, specifically
designed for the Women's Health Nurse Practitioner (WHNP) certification examination. The content is
systematically organized to cover all major domains of women's health, from reproductive physiology and
contraception to complex gynecological conditions and menopausal management. Each question is crafted to test
clinical reasoning, application of evidence-based guidelines, and critical decision-making skills. The answers are
accompanied by detailed rationales that explain the correct and incorrect options, facilitating a deep
understanding of the subject matter. This resource is an essential study aid for WHNP candidates seeking to
Page 1
,validate their knowledge and achieve a passing score on the boards in the 2026-2027 cycle.
Keywords:
WHNP board review, Women's health nurse practitioner, Certification exam prep, Gynecology questions,
Obstetrics and maternity care, Contraception and family planning, Menopause management, Evidence-based
practice
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining why it is correct and why the other options are incorrect. This
format enhances understanding and retention of key concepts.
Compliance Checklist:
Aligned with the latest WHNP certification exam blueprint
All questions verified by expert WHNP educators and clinicians
References current clinical guidelines and evidence-based literature
Includes rationales for both correct and incorrect answers
Suitable for self-assessment and focused review
Updated for the 2026-2027 academic year
Content Area Overview:
Content Area Questions Key Topics Weight
Primary Care in Women's Health 1-20 Health maintenance, screening, 13%
immunizations, lifestyle counseling
Reproductive Health and 21-40 Contraceptive methods, family planning, 13%
Contraception preconception care, abortion care
Prenatal Care 41-60 First trimester, second trimester, third 13%
trimester, prenatal testing, high-risk
pregnancy
Intrapartum and Postpartum Care 61-80 Labor and delivery, postpartum 13%
complications, lactation, newborn care
Gynecological Disorders 81-100 Menstrual disorders, pelvic pain, fibroids, 13%
endometriosis, pelvic organ prolapse
Menopause and Perimenopause 101-115 Hormone therapy, vasomotor symptoms, 10%
osteoporosis, genitourinary syndrome
Breast Health 116-125 Breast cancer screening, benign breast 7%
conditions, breast cancer risk assessment
Sexually Transmitted Infections 126-135 STI screening, treatment, prevention, partner 7%
management
Infertility and Reproductive 136-145 Infertility evaluation, ovulation induction, 7%
Endocrinology PCOS, amenorrhea
Adolescent Gynecology and 146-150 Adolescent menstrual issues, LGBTQ+ 4%
Special Populations health, care of women with disabilities
Page 2
,Q1. A 45-year-old woman presents with new-onset hypertension and hirsutism. Labs
show morning cortisol 25 µg/dL (normal 5-25), ACTH 5 pg/mL (normal 10-60), and a
24-hour urine cortisol elevated. Which test best distinguishes an adrenal adenoma
from an ACTH-independent bilateral micronodular hyperplasia?
A. High-dose dexamethasone suppression test
B. CRH stimulation test
C. Adrenal CT with contrast washout
D. Bilateral inferior petrosal sinus sampling
Correct Answer: C. Adrenal CT with contrast washout
Rationale: In ACTH-independent Cushing's syndrome (low ACTH, elevated cortisol), the
cause is adrenal. High-dose dexamethasone suppression and CRH stimulation are used to
differentiate pituitary vs. ectopic ACTH, not adrenal causes. Adrenal CT with contrast
washout is the key imaging to distinguish adenoma (lipid-rich, rapid washout) from
carcinoma or hyperplasia. BIPSS is for pituitary ACTH. Thus, C is correct.
Why Wrong:
A - High-dose dexamethasone suppression is used for ACTH-dependent Cushing's,
not ACTH-independent.
B - CRH stimulation is used to differentiate pituitary from ectopic ACTH, not adrenal
causes.
D - Bilateral inferior petrosal sinus sampling is invasive and only for
ACTH-dependent disease.
Reference: Melmed, S. et al. (2024). Williams Textbook of Endocrinology, 14th ed., Ch.
15.
Q2. In a patient with a history of recurrent early pregnancy loss and a lupus
anticoagulant, which combination of therapies has the best evidence to improve live
birth rate?
A. Low-dose aspirin alone
B. Unfractionated heparin plus low-dose aspirin
C. Low-molecular-weight heparin alone
D. Prednisone plus low-dose aspirin
Correct Answer: B. Unfractionated heparin plus low-dose aspirin
Rationale: Antiphospholipid syndrome (APS) with recurrent pregnancy loss is treated with
prophylactic-dose heparin plus low-dose aspirin, which significantly improves live birth
rates compared to aspirin alone. LMWH alone is less studied than LMWH plus aspirin.
Prednisone is not recommended due to maternal and fetal side effects. Thus, B is correct.
Why Wrong:
A - Aspirin alone is insufficient in APS; combination therapy is superior.
C - LMWH alone is not the standard; it is combined with aspirin.
Page 3
, D - Corticosteroids are not recommended in APS due to adverse effects and lack of
benefit.
Reference: ACOG Practice Bulletin No. 132 (Reaffirmed 2023). Antiphospholipid
Syndrome.
Q3. A 30-year-old woman with a BRCA1 mutation presents for risk-reducing options.
She has completed childbearing. Which intervention is most effective in reducing
ovarian cancer mortality?
A. Annual transvaginal ultrasound and CA-125 screening
B. Prophylactic bilateral salpingo-oophorectomy
C. Oral contraceptive pill use for 10 years
D. Tubal ligation
Correct Answer: B. Prophylactic bilateral salpingo-oophorectomy
Rationale: For BRCA1 mutation carriers, risk-reducing bilateral salpingo-oophorectomy
(RRSO) reduces ovarian cancer risk by ~80-90% and is the most effective intervention for
mortality reduction. Screening with CA-125 and ultrasound is not effective for early
detection. OCPs reduce risk but not as much as RRSO. Tubal ligation may reduce risk but
not to the same extent. Thus, B is correct.
Why Wrong:
A - Screening has not been shown to reduce mortality in high-risk women.
C - OCPs reduce risk but are less effective than surgery and have other risks.
D - Tubal ligation has some risk reduction but is inferior to RRSO.
Reference: NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian,
and Pancreatic, v.1.2024.
Q4. Which of the following best explains the mechanism of action of selective estrogen
receptor modulators (SERMs) in the treatment of breast cancer?
A. They inhibit aromatase, reducing estrogen synthesis.
B. They competitively antagonize estrogen at the receptor in breast tissue.
C. They downregulate HER2 receptors on tumor cells.
D. They induce apoptosis by binding to the estrogen receptor and activating death
domains.
Correct Answer: B. They competitively antagonize estrogen at the receptor in breast
tissue.
Rationale: SERMs like tamoxifen bind to estrogen receptors and exert antagonistic effects
in breast tissue, blocking estrogen-mediated growth. They do not inhibit aromatase; that is
the action of aromatase inhibitors. They do not target HER2. They do not activate death
domains; they modulate transcription. Thus, B is correct.
Page 4
150 Verified Questions - 150 Questions with Answers
WHNP Boards 2026-150 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for candidates aspiring to pass
the Women's Health Nurse Practitioner (WHNP) board certification. It contains 150 verified questions
and answers that reflect the current scope and standards of practice, ensuring a thorough review of
essential clinical and theoretical knowledge. Each question is accompanied by expert solutions and
rationales, designed to reinforce learning and test-taking strategies. This resource is an indispensable
tool for achieving a high score on the WHNP boards in the 2026-2027 academic year.
Key Features:
Comprehensive review of primary care in women's health across the lifespan
In-depth coverage of reproductive health and contraception management
Detailed questions on prenatal, intrapartum, and postpartum care
Focus on gynecological disorders and common infections
Menopause and perimenopause management strategies
Breast health assessment and disease management
Sexually transmitted infections (STIs) screening and treatment
Infertility evaluation and basic management
Adolescent gynecology and pediatric gynecological concerns
Health promotion, screening, and disease prevention guidelines
Pharmacology relevant to women's health practice
Evidence-based practice and research utilization
Ethical and legal issues in women's health
Cultural competence and patient-centered care
Interprofessional collaboration and referral pathways
Patient education and counseling techniques
Quality improvement and safety in clinical practice
Professional role and leadership in advanced practice nursing
Updates for 2026:
- Updated to align with the latest NCC WHNP exam blueprint and competencies
- Incorporates 2026 clinical practice guidelines from ACOG, USPSTF, and CDC
- Includes new questions on telehealth and digital health in women's health
- Reflects current evidence on LGBTQ+ health considerations and inclusive care
- Enhanced rationales with recent research findings and expert consensus
Abstract:
This exam preparation document is a scholarly compilation of 150 board-style questions and answers, specifically
designed for the Women's Health Nurse Practitioner (WHNP) certification examination. The content is
systematically organized to cover all major domains of women's health, from reproductive physiology and
contraception to complex gynecological conditions and menopausal management. Each question is crafted to test
clinical reasoning, application of evidence-based guidelines, and critical decision-making skills. The answers are
accompanied by detailed rationales that explain the correct and incorrect options, facilitating a deep
understanding of the subject matter. This resource is an essential study aid for WHNP candidates seeking to
Page 1
,validate their knowledge and achieve a passing score on the boards in the 2026-2027 cycle.
Keywords:
WHNP board review, Women's health nurse practitioner, Certification exam prep, Gynecology questions,
Obstetrics and maternity care, Contraception and family planning, Menopause management, Evidence-based
practice
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining why it is correct and why the other options are incorrect. This
format enhances understanding and retention of key concepts.
Compliance Checklist:
Aligned with the latest WHNP certification exam blueprint
All questions verified by expert WHNP educators and clinicians
References current clinical guidelines and evidence-based literature
Includes rationales for both correct and incorrect answers
Suitable for self-assessment and focused review
Updated for the 2026-2027 academic year
Content Area Overview:
Content Area Questions Key Topics Weight
Primary Care in Women's Health 1-20 Health maintenance, screening, 13%
immunizations, lifestyle counseling
Reproductive Health and 21-40 Contraceptive methods, family planning, 13%
Contraception preconception care, abortion care
Prenatal Care 41-60 First trimester, second trimester, third 13%
trimester, prenatal testing, high-risk
pregnancy
Intrapartum and Postpartum Care 61-80 Labor and delivery, postpartum 13%
complications, lactation, newborn care
Gynecological Disorders 81-100 Menstrual disorders, pelvic pain, fibroids, 13%
endometriosis, pelvic organ prolapse
Menopause and Perimenopause 101-115 Hormone therapy, vasomotor symptoms, 10%
osteoporosis, genitourinary syndrome
Breast Health 116-125 Breast cancer screening, benign breast 7%
conditions, breast cancer risk assessment
Sexually Transmitted Infections 126-135 STI screening, treatment, prevention, partner 7%
management
Infertility and Reproductive 136-145 Infertility evaluation, ovulation induction, 7%
Endocrinology PCOS, amenorrhea
Adolescent Gynecology and 146-150 Adolescent menstrual issues, LGBTQ+ 4%
Special Populations health, care of women with disabilities
Page 2
,Q1. A 45-year-old woman presents with new-onset hypertension and hirsutism. Labs
show morning cortisol 25 µg/dL (normal 5-25), ACTH 5 pg/mL (normal 10-60), and a
24-hour urine cortisol elevated. Which test best distinguishes an adrenal adenoma
from an ACTH-independent bilateral micronodular hyperplasia?
A. High-dose dexamethasone suppression test
B. CRH stimulation test
C. Adrenal CT with contrast washout
D. Bilateral inferior petrosal sinus sampling
Correct Answer: C. Adrenal CT with contrast washout
Rationale: In ACTH-independent Cushing's syndrome (low ACTH, elevated cortisol), the
cause is adrenal. High-dose dexamethasone suppression and CRH stimulation are used to
differentiate pituitary vs. ectopic ACTH, not adrenal causes. Adrenal CT with contrast
washout is the key imaging to distinguish adenoma (lipid-rich, rapid washout) from
carcinoma or hyperplasia. BIPSS is for pituitary ACTH. Thus, C is correct.
Why Wrong:
A - High-dose dexamethasone suppression is used for ACTH-dependent Cushing's,
not ACTH-independent.
B - CRH stimulation is used to differentiate pituitary from ectopic ACTH, not adrenal
causes.
D - Bilateral inferior petrosal sinus sampling is invasive and only for
ACTH-dependent disease.
Reference: Melmed, S. et al. (2024). Williams Textbook of Endocrinology, 14th ed., Ch.
15.
Q2. In a patient with a history of recurrent early pregnancy loss and a lupus
anticoagulant, which combination of therapies has the best evidence to improve live
birth rate?
A. Low-dose aspirin alone
B. Unfractionated heparin plus low-dose aspirin
C. Low-molecular-weight heparin alone
D. Prednisone plus low-dose aspirin
Correct Answer: B. Unfractionated heparin plus low-dose aspirin
Rationale: Antiphospholipid syndrome (APS) with recurrent pregnancy loss is treated with
prophylactic-dose heparin plus low-dose aspirin, which significantly improves live birth
rates compared to aspirin alone. LMWH alone is less studied than LMWH plus aspirin.
Prednisone is not recommended due to maternal and fetal side effects. Thus, B is correct.
Why Wrong:
A - Aspirin alone is insufficient in APS; combination therapy is superior.
C - LMWH alone is not the standard; it is combined with aspirin.
Page 3
, D - Corticosteroids are not recommended in APS due to adverse effects and lack of
benefit.
Reference: ACOG Practice Bulletin No. 132 (Reaffirmed 2023). Antiphospholipid
Syndrome.
Q3. A 30-year-old woman with a BRCA1 mutation presents for risk-reducing options.
She has completed childbearing. Which intervention is most effective in reducing
ovarian cancer mortality?
A. Annual transvaginal ultrasound and CA-125 screening
B. Prophylactic bilateral salpingo-oophorectomy
C. Oral contraceptive pill use for 10 years
D. Tubal ligation
Correct Answer: B. Prophylactic bilateral salpingo-oophorectomy
Rationale: For BRCA1 mutation carriers, risk-reducing bilateral salpingo-oophorectomy
(RRSO) reduces ovarian cancer risk by ~80-90% and is the most effective intervention for
mortality reduction. Screening with CA-125 and ultrasound is not effective for early
detection. OCPs reduce risk but not as much as RRSO. Tubal ligation may reduce risk but
not to the same extent. Thus, B is correct.
Why Wrong:
A - Screening has not been shown to reduce mortality in high-risk women.
C - OCPs reduce risk but are less effective than surgery and have other risks.
D - Tubal ligation has some risk reduction but is inferior to RRSO.
Reference: NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian,
and Pancreatic, v.1.2024.
Q4. Which of the following best explains the mechanism of action of selective estrogen
receptor modulators (SERMs) in the treatment of breast cancer?
A. They inhibit aromatase, reducing estrogen synthesis.
B. They competitively antagonize estrogen at the receptor in breast tissue.
C. They downregulate HER2 receptors on tumor cells.
D. They induce apoptosis by binding to the estrogen receptor and activating death
domains.
Correct Answer: B. They competitively antagonize estrogen at the receptor in breast
tissue.
Rationale: SERMs like tamoxifen bind to estrogen receptors and exert antagonistic effects
in breast tissue, blocking estrogen-mediated growth. They do not inhibit aromatase; that is
the action of aromatase inhibitors. They do not target HER2. They do not activate death
domains; they modulate transcription. Thus, B is correct.
Page 4
